Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

MM+M Podcast explores AI-powered audience intelligence with Inizio Evoke

January 7, 2026 | Intelligent Commercialization 

The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what AI-powered audience intelligence means for life sciences organizations heading into 2026.

Evoke-Podcast

How AI and LLMs are shaping audience intelligence in life sciences

In the episode, they examine how life sciences companies are approaching AI and Large Language Models (LLMs), the challenges created by gaps in data sets, and why context and real behavior matter when predicting how healthcare professionals and patients engage.

Why real behavior and high-quality data are critical for predictive accuracy

The discussion focuses on several key themes, including: 

  • The limitations of narrow or closed data inputs and how they restrict prediction accuracy 
  • The importance of understanding real behavior beyond a single organization’s data 
  • Why high-quality, holistic data sets are essential to improving LLM performance 
  • The role of subject matter experts in providing context that general-purpose models currently lack 
  • How data quality directly influences the usefulness and reliability of AI tools 

Together, Jamie and Iris highlight how more precise, behavior-informed audience intelligence can support better decision-making as AI becomes increasingly central to life sciences marketing and engagement. 

Listen to the full MM+M Podcast episode: “Beyond the algorithm: What AI-powered audience intelligence really means in 2026.”

Intelligent Commercialization™ in action

This perspective is core to how Inizio delivers Intelligent Commercialization™ – our unified, expert-driven approach that connects proprietary data, technology, and AI to unlock measurable impact across the product lifecycle. Platforms such as Cognitev™ and Predictev™ (referenced in the discussion) translate over 35M hours of real-world behavior into actionable intelligence, enabling clients to anticipate shifts, optimize engagement, and make smarter decisions with confidence.

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Preparing for ASH 2025: Pharma’s role in hematology innovation

As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

AI without limits: A smarter, integrated approach to Medical Affairs

At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...

What to expect from Obesity Week 2025: Key trends shaping the future of obesity care

Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.

AI with intent: How Inizio is redefining pharma through precision and partnership

At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...

Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight

Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.

Delivering purposeful solutions at Obesity Week 2025

We’re attending Obesity Week 2025, the world’s leading event dedicated to obesity research and care, to showcase how our integrated expertise is advancing progress in obesity and cardiometabolic health.

Inizio strengthens executive team with new leadership appointments

Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™...

Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards

Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across...

Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care

Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.

Inizio appoints Ryan Quigley as CEO

Inizio have appointed Ryan Quigley as Chief Executive Officer, effective 9 September 2025. Paul Taaffe will remain closely involved with the company as an Advisor and board member going forward. ...